ALNY Q2 2025 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$774M+17.3% YoY

Gross Profit

$631M81.5% margin

Operating Income

-$16M-2.1% margin

Net Income

-$66M-8.6% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

+30.2%

Cash Flow

Operating Cash Flow

$154M

Free Cash Flow

$139M

Stock-Based Comp.

$112M

Balance Sheet

Total Assets

$4.6B

Total Liabilities

$4.3B

Stockholders' Equity

$251M

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$774M	$660M	+17.3%
Gross Profit	$631M	$591M	+6.7%
Operating Income	-$16M	$49M	-133.3%
Net Income	-$66M	-$17M	-292.4%

Revenue Segments

Product

$672M83%

GIVLAARI

$81M10%

ONPATTRO

$53M7%

Geographic Segments

UNITED STATES

$361M73%

Europe

$93M19%

Non-US Or Europe

$38M8%